Study of JYP0322 for untreated ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted therapy for people with a specific type of advanced lung cancer that has not been treated before. The drug JYP0322 may help shrink tumors or slow cancer growth, and the study checks if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced (stage IIIB, IIIC, or IV) non-small cell lung cancer that has a specific change called ROS1.
- You must not have had any prior treatment that targets ROS1, and no more than one line of standard chemotherapy.
- You must be able to provide a tumor sample or agree to a biopsy.
- You must be generally healthy enough to receive treatment, with good organ function.
- If you have brain metastases, they must be stable and not causing symptoms, and you must not have certain types of brain involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
This trial tests an experimental drug called JYP0322 for people with advanced solid tumors that have a specific genetic change called a ROS1 fusion. The goal is to see if the drug is safe and effective against these tumors.
This trial tests a new drug called JYP0322 against standard chemotherapy for people with a specific type of lung cancer that has the ROS1 gene change. It is for those who have already tried one or two ROS1-targeted treatments and need another option.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This study tests an oral drug called lorlatinib in people with ROS1-positive lung cancer that has spread to the brain. The drug targets the ROS1 mutation and aims to shrink brain tumors and improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.